Connect public, paid and private patent data with Google Patents Public Datasets

Composition And Device For In Vivo Cartilage Repair

Download PDF

Info

Publication number
US20090297605A1
US20090297605A1 US12463108 US46310809A US20090297605A1 US 20090297605 A1 US20090297605 A1 US 20090297605A1 US 12463108 US12463108 US 12463108 US 46310809 A US46310809 A US 46310809A US 20090297605 A1 US20090297605 A1 US 20090297605A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
cartilage
bp
nanospheres
release
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12463108
Inventor
Brent L. Atkinson
Pedro Bittman
James J. Benedict
John Ranieri
Marsha L. Whitney
Donald Chickering
Original Assignee
Atkinson Brent L
Pedro Bittman
Benedict James J
John Ranieri
Whitney Marsha L
Donald Chickering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30756Cartilage endoprostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06166Sutures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • A61F2002/2817Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004The prosthesis made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30036The prosthesis made from materials having different values of a given property at different locations within the same prosthesis differing in release or diffusion time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30667Features concerning an interaction with the environment or a particular use of the prosthesis
    • A61F2002/30677Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0035Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in release or diffusion time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00365Proteins; Polypeptides; Degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624Nanocapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/12Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908Mechanical repair performed/surgical
    • Y10S977/91Strengthening cell or tissue
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/914Protein engineering

Abstract

The composition as described serves for in vivo cartilage repair. It basically consists of a naturally derived osteoinductive and/or chondroinductive mixture of factors (e.g. derived from bone) or of a synthetic mimic of such a mixture combined with a nanosphere delivery system. A preferred mixture of factors is the combination of factors isolated from bone, known as BP and described by Poser and Benedict (WO 95/13767). The nanosphere delivery system consists of nanospheres defined as polymer particles of less than 1000 nm in diameter (whereby the majority of particles preferably ranges between 200-400 nm) in which nanospheres the combination of factors is encapsulated. The nanospheres are loaded with the mixture of factors in a weight ratio of 0.001 to 17% (w/w), preferably of 1 to 4% (w/w) and have a release profile with an initial burst of 10 to 20% of the total load over the first 24 hours and a long time release of at least 0.1 per day during at least seven following days. The nanospheres are composed of e.g. ((D,L)lactic acid/glycolic acid)-copolymer (PLGA). The loaded nanospheres are e.g. made by phase inversion. The composition is advantageously utilized as a device comprising any biodegradable matrix in which the nanospheres loaded with the factor combination is contained.

Description

  • [0001]
    This application is a continuation of U.S. Ser. No. 11/433,968, filed May 15, 2006, which is a continuation of U.S. Ser. No. 10/386,946, filed Mar. 11, 2003, which is a continuation of U.S. Ser. No. 09/485,594, now issued as U.S. Pat. No. 6,582,471 on Jun. 24, 2003, which is a § 371 filing of International Application No. PCT/EP98/05100. All applications are incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Articular cartilage, an avascular tissue found at the ends of articulating bones, has no natural capacity to heal. During normal cartilage ontogeny, mesenchymal stem cells condense to form areas of high density and proceed through a series of developmental stages that ends in the mature chondrocyte. The final hyaline cartilage tissue contains only chondrocytes that are surrounded by a matrix composed of type II Collagen, sulfated proteoglycans, and additional proteins. The matrix is heterogenous in structure and consists of three morphologically distinct zones: superficial, intermediate, and deep. Zones differ among collagen and proteoglycan distribution, calcification, orientation of collagen fibrils, and the positioning and alignment of chondrocytes (Archer et al., J. Anat. 189(1): 23-35, 1996; Morrison et al., J. Anat, 189(1): 9-22 1996, Mow et al., Biomaterials 13(2): 67-97, 1992). These properties provide the unique mechanical and physical parameters to hyaline cartilage tissue.
  • [0003]
    In 1965, a demineralized extraction from bovine long bones was found to induce endochondral bone formation in the rat subcutaneous assay (Urist Science 150: 893-899. 1965). Seven individual factors termed Bone Morphogenetic Proteins (BMPs) were isolated to homogeneity and. because of significant sequence homology classified as members of the TGFβ superfamily of proteins (Wozney, et al., Science 242: 1528-34, 1988; Wang et al., Proc. Nat. Acad. Sci. 87: 2220-2224, 1990). These individual recombinantly-produced factors also induce ectopic bone formation in the rat model (Luyten et al, J. Biol. Chem. 264: 13377-80. 1989; Celeste et al., Proc. Nat. Acad. Sci. 87: 9843-50, 1990). In addition in vitro tests have demonstrated that both BMP-2 and TGFβ-1 induce mesenchymal stem cells to form cartilage (Denker. et al., Differentiation 59(i): 25-34. 1995; Denker et al., 41st Ann. Orthop. Res. Society 465: 1995). Both BMP-7 and BMP-2 have been shown to enhance matrix production of chondrocytes in vitro (Flechtenmacher J. Arthritis Rheum. 39(11): 1896-904.1996: Sailor et al. J. Orthop. Res. 14: 937-945, 1996). From these data we can conclude that not only are the BMPs important regulators of osteogenesis but that they also play crucial roles during chondrogenic development in vitro.
  • [0004]
    A partially-purified protein mixture from bovine long bones termed BP (Bone Protein), also induces cartilage and bone formation in the rat subcutaneous assay (Poser and Benedict. WO95/13767). BP in combination with calcium carbonate promotes bone formation in the body. In vitro, BP induces mesenchymal stem cells to differentiate specifically to the cartilage lineage. in high yields, and to late stages of maturation (Atkinson et al., J. Cellular Biochem. 65: 325-339, 1997).
  • [0005]
    The molecular mechanism for cartilage and bone formation has been partially elucidated. Both BMP and TGFβ molecules bind to cell surface receptors (the BMP/TGFβ receptors), which initiates a cascade of signals to the nucleus that promotes proliferation, differentiation to cartilage, and! or differentiation to bone (Massague Cell 85: 947-950, 1996).
  • [0006]
    In 1984, Urist described a substantially pure, but not recombinant BMP, combined with a biodegradable polylactic acid polymer delivery system for bone repair (U.S. Pat. No. 4,563,489). This system blends together equal quantities of BMP and polylactic acid (PLA) powder (100 μ.g of each) and decreases the amount of BMP required to promote bone repair.
  • [0007]
    Hunziker (U.S. Pat. No. 5,368,858; U.S. Pat. No. 5,206,023) describes a cartilage repair composition consisting of a biodegradable matrix, a proliferation and/or chemotactic agent, and a transforming factor. A two stage approach is used where each component has a specific function over time. First, a specific concentration of proliferation/chemotactic agent fills the defect with repair cells. Secondly, a larger transforming factor concentration transforms repair cells into chondrocytes. Thereby the proliferation agent and the transforming agent may both be TGFβ differing in concentration only. In addition, the patent discloses a liposome encapsulation method for delivering TGFβ-1 serving as transformation agent.
  • [0008]
    Hattersley et al. (WO 96/39170) disclose a two factor composition for inducing cartilaginous tissue formation using a cartilage formation-inducing protein and a cartilage maintenance inducing protein. Specific recombinant cartilage formation inducing protein(s) are specified as BMP-13, MP-52, and BMP-12, and cartilage maintenance-inducing protein(s) are specified as BMP-9. In one embodiment, BMP-9 is encapsulated in a resorbable polymer system and delivered to coincide with the presence of cartilage formation inducing protein(s).
  • [0009]
    Laurencin et al., (U.S. Pat. No. 5,629,009) disclose a chondrogenesis-inducing device, consisting of a poly anhydride and polyorthoester, that delivers water soluble proteins derived from demineralized bone matrix, TGFβ, EGF, FGF, or PDGF.
  • [0010]
    The results of the approaches to cartilage repair as cited above are encouraging but they are not satisfactory. In particular, the repair tissue arrived at is not fully hyaline in appearance and/or it does not contain the proper chondrocyte organization. Furthermore, previous approaches to cartilage repair have been addressed to very small defects and have not been able to solve problems associated with repair of large, clinically relevant defects.
  • [0011]
    One reason that previous approaches failed to adequately repair cartilage may be that they were not able to recapitulate natural cartilage ontogeny faithfully enough, this natural ontogeny being based on a very complicated system of different factors, factor combinations and factor concentrations with temporal and local gradients. A single recombinant growth factor or two recombinant growth factors may lack the inductive complexity to mimic cartilage development to a sufficient degree and/or the delivery systems used may not have been able to mimic the gradient complexity of the natural system to a satisfactory degree.
  • [0012]
    Previous approaches may also have failed because growth factor concentrations were not able to be maintained over a sufficient amount of time, which would prevent a full and permanent differentiation of precursor cells to chondrocytes. The loss of growth factor could be caused by diffusion, degradation, or by cellular internalization that bypasses the BMP/TGFβ receptors. Maintaining a sufficient growth factor concentration becomes particularly important in repair of large sized defects that may take several days or several weeks to fully repopulate with cells.
  • [0013]
    The object of this invention is to create (J. composition for improved cartilage repair in vivo. The inventive composition is to enable in vivo formation of repair cartilage tissue which tissue resembles endogenous cartilage (in the case of articular cartilage with its specific chondrocyte spatial organization and superficial, intermediate, and deep cartilage zones) more closely than repair tissue achieved using known compositions for inducing cartilage repair. A further object of the invention is to create a device for cartilage repair which device contains the inventive composition.
  • [0014]
    This object is achieved by the composition and the device as defined by the claims.
  • BRIEF DESCRIPTION OF THE INVENTION
  • [0015]
    The inventive composition basically consists of a naturally derived osteoinductive and/or chondroinductive mixture of factors (e.g, derived from bone) or of a synthetic mimic of such a mixture combined with a nanosphere delivery system. A preferred mixture of factors is the combination of factors isolated from bone, known as BP and described by Poser and Benedict (WO 95/13767). The nanosphere delivery system consists of nanospheres defined as polymer particles of less than 1000 nm in diameter (whereby the majority of particles preferably ranges between 200-400 nm) in which nanospheres the combination of factors is encapsulated. The nanospheres are loaded with the mixture of factors in a weight ratio of 0.001 to 17% (w/w), preferably of 1 to 4% (w/w) and have an analytically defined release profile (see description regarding FIG. 2) showing an initial burst of 10 to 20% of the total load over the first 24 hours and a long time release of at least 0.1 per day during at least seven following days, preferably of 0.1 to 1% over the following 40 to 60 days. The nanospheres are composed of e.g. (lactic acid-glycolic acid)-copolymers (Poly-(D,L)lactic acid-glycolic acid) made of 20 to 80% lactic acid and 80 to 20% of glycolic acid, more preferably of, 50% lactic acid and 50% of glycolic acid.
  • [0016]
    The loaded nanospheres are e.g. made by phase inversion according to Mathiowitz et al. (Nature, 386: 410-413, 1997) or by other methods known to those skilled in the art (Landry, Ph.D Thesis, Frankfurt, Germany).
  • [0017]
    The inventive composition is advantageously utilized as a device comprising any biodegradable matrix including collagen type I and II, and hyaluronic acid in which matrix the nanospheres loaded with the factor combination is contained. The matrix can be in the form of a sponge, membrane, film or gel. The matrix should be easily digestible by migrating cells, should be of a porous nature to enhance cell migration, and/or should be able to completely fill the defect area without any gaps.
  • [0018]
    It is surprisingly found that the inventive composition consisting of an osteoinductive and/or chondroinductive combination of factors (e.g, derived from natural tissue) encapsulated in nanospheres as specified above, if applied to a defect area of an articular cartilage, leads to the transformation of virtually all precursor cells recruited to the repair area to chondrocytes, and furthermore, leads to a homogenous chondrocyte population of the repair area and to a chondrocyte order and anisotropic appearance as observed in endogenous hyaline cartilage. These findings encourage the prospect that the inventive composition may lead to significant improvements also regarding repair of large defects.
  • [0019]
    As mentioned above, instead of an osteoinductive and/or chondroinductive mixture of factors derived from bone (BP), the inventive composition may comprise natural factor mixtures derived from other tissues (e.g. cartilage, tendon, meniscus or ligament) or may even be a synthetic mimic of such a mixture having an osteoinductive and/or chondroinductive effect. Effective mixtures isolated from natural tissue seem to contain a combination of proliferation, differentiation, and spatial organizing proteins which in combination enhance the tissue rebuilding capacity more effectively than single proteins (e.g. recombinant proteins).
  • [0020]
    The specified, analytically defined release profile of such factor mixtures from nanospheres results in the formation of concentration gradients of proliferation and differentiation factors, which obviously mimics the complex gradients of factors observed during natural development very well. The nanosphere extended release profile is sufficient to provide growth factor during the time frame that repair cells arrive into the matrix. The release profile obviously leads to a homogenous population of a matrix with precursor cells, to full differentiation of virtually all of the precursor cells to chondrocytes, and to the formation of an endogenous hyaline cartilage structure.
  • [0021]
    Another advantage of the inventive composition is that when the nanospheres are placed in a matrix to form a device for cartilage repair, they are randomly distributed and remain in place when in a joint cartilage defect. During cellular infiltration and differentiation, the nanospheres are in the correct position over the correct time frame.
  • [0022]
    Nanospheres have been demonstrated to adhere to the gastrointestinal mucus and cellular linings after oral ingestion (Mathiowitz et al., Nature, 386 410-413 1997). We envisage that nanospheres also adhere to cartilage precursor cells and furthermore, may also adhere to BMP/TGFβ receptors located on the cell membrane. This property allows localized high-efficiency delivery to the target cells and/or receptors. Because of the nanosphere small size and the chemical properties, they are more effective than liposomes or diffusion controlled delivery systems. The efficient delivery to the receptors will facilitate chondrogenesis.
  • [0023]
    Derived from the above findings, we envisage the following mechanism for cartilage repair using the effect of the inventive composition. During the first 24 hours (initial burst) 10 to 20% of the total load of the factor mixture is released from the nanospheres into the matrix and diffuses into the synovial environment. Following the initial burst, the nanospheres begin to release factors at a slow rate, which produces gradients of proliferation, differentiation, and spatial organizing proteins. In response to such gradients, precursor cells migrate to the defect site. The loaded nanospheres adhere to cartilage precursor cells and to the BMP and TGFβ receptors to provide localized highly efficient delivery. The precursor cells become differentiated to chondrocytes and secrete type II collagen and cartilage-specific proteoglycans. The composition of the present invention stimulates differentiation of virtually all of these cells to overt chondrocytes and induces an ordered cartilage structure which closely resembles hyaline cartilage. Furthermore, we envisage is that this release system will allow homogenous repair of large defect sites and repair of defects from patients with low quantities of precursor cells,
  • [0024]
    For in vivo cartilage repair, the inventive device consisting of a matrix and the loaded nanospheres is placed in a chondral lesion that was caused by trauma, arthritis, congenital, or other origin. The damage can result in holes or crevices or can consist of soft, dying, or sick cartilage tissue that is removed surgically prior to implantation of the device. Because of the unique properties of the inventive device precursor cells populate the matrix, differentiate to chondrocytes, and form hyaline cartilage.
  • [0025]
    Application of the inventive composition (without matrix) e.g. by injection can be envisaged also, in particular in the case of small defects. Thereby at least 2 μg of the composition per ml of defect size is applied or at least 20 ng of the osteoinductive and/or chondroinductive mixture encapsulated in the nanospheres is applied per ml defect size.
  • [0026]
    The inventive composition and the inventive device are suitable for repair of cartilage tissue in general. in particular for articular cartilage and for meniscus cartilage.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0027]
    The following figures illustrate the physical and chemical parameters of the inventive composition, the in vitro cartilage inductive activity of BP released from nanospheres and in vivo repair of an articular cartilage defect using the inventive device.
  • [0028]
    FIG. 1 shows a scanning electron micrograph of BP-loaded nanospheres;
  • [0029]
    FIG. 2 shows the release profile (cumulative release vs. time) of the inventive composition;
  • [0030]
    FIG. 3 shows the release profile of the inventive composition compared with release profiles of nanosphere delivery systems loaded with other proteins;
  • [0031]
    FIG. 4 shows the volume of a cartilage defect vs. the days required for populating the defect with repair cells;
  • [0032]
    FIG. 5 shows micromass cultures in the presence or absence of nanospheres loaded with BP;
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0033]
    FIG. 1 shows a scanning electron micrograph of BP-loaded nanospheres. The microparticle sizes range from 100-1000 run with the majority of individual particles ranging between 200-400 nm.
  • [0034]
    The release rate profile of the inventive composition was determined by in vitro analysis of BP delivered from nanospheres. These nanospheres were made by phase inversion according to the method as disclosed by Mathiowitz et al. (Nature 386, 410-414, 1997) of ((DL)lactic acid/glycolic acid)-copolymer coring the two acids in a weight ratio of 50:50 and they were loaded with 1% and with 4% of BP.
  • [0035]
    For determination of the release rate profile, the nanospheres were placed in a sterile saline solution and incubated at 37° C. BP released into the supernatant was measured using a BCA assay (Pierce). BP released from the nanospheres as specified shows two successive and distinct profile parts: a fast release (initial burst) of approximately 10 to 20% of the loaded BP over the first 24 hours and a slow release of 0.1 to 1% per day (cumulative 40% to 50%) over 40 to 60 days (FIG. 2).
  • [0036]
    The release is intermediate between zero-order and first-order kinetics. Both the 1% and 4% encapsulated BP have similar release profiles.
  • [0037]
    For attaining release rate profiles as specified above and as necessary for the improved results in cartilage repair the nanospheres are to be adapted accordingly when using factor mixtures other than BP. Thereby, e.g the composition of the nanosphere copolymer, the molecular weight of the polymer molecules and/or the loading percentage of the nanospheres may be changed. The optimum nanosphere character for each specific case has to be found experimentally whereby the release rate profile is analyzed in vitro as described above.
  • [0038]
    In the same way, the nanosphere delivery system can be modified regarding the percentage of BP to be released in the first 24 hours, percentage of BP to be released after 24 hours and/or length of time after the first 24 hours during which the remainder of BP is released. In addition, the percentage of BP loaded to the nanospheres is of course variable too, whereby for obtaining the results as described for the specified composition, all the modifications are to be chosen such that the resulting delivery keeps within the range as specified.
  • [0039]
    All of the above parameters can be modified to account for the patient's age, sex, diet. defect location, amount of blood present in the defect, and other clinical factors to provide optimal cartilage repair. For example, nanospheres with longer release rates are used for treating larger defects and/or for patients with fewer precursor cells (e.g. older patients or patients with degenerative symptoms). In contrast, patients with larger quantities of progenitor cells and/or smaller defects may require a shorter release rate profile.
  • [0040]
    FIG. 3 shows the release profile as shown in FIG. 2 for nanospheres as specified above loaded with BP and with other proteins (same loading percentages) such as BSA (bovine serum albumin) or lysozyme. The drastically different release characteristics shows that the profile is dependent on the protein type also. The same is valid for a more hydrophobic mixture of bovine bone derived proteins (PIBP).
  • [0041]
    FIG. 3 illustrates the singularity of the inventive combination consisting of the specific delivery system (nanospheres as specified above encapsulating the factors) and the specific protein mixture (BP) which is obviously the key to the improved results in cartilage repair as observed when using the inventive composition or device.
  • [0042]
    To determine the length of time required for precursor cell repopulation of different sized defects, the following calculation was performed. We estimate that approximately 50,000 cells are recruited to the defect/day. Since the cellular density of cartilage is about 4×107 cells/ml, a 10 μl volume defect will take approximately 8 days to fill with cells. FIG. 4 plots the number of days required to fill different volume defects with cells. The Figure assumes an infinite supply of cells and a constant rate of cell attraction to the defect site, The graph demonstrates that the larger a defect size is, the more time is required to completely fill it with cells. Since a 60 μl volume defect will take over 45 days to fill, this Figure demonstrates the necessity for a long term release of factors to induce differentiation of the precursor cells over up to a two month period.
  • [0043]
    To determine whether BP bioactivity is harmed by the encapsulation process and to determine whether the released BP was fully bioactive, the following assay was performed. Previously, it was demonstrated that 10T1/2 micromass cultures exposed to BP induce formation of a three dimensional spheroid structure that can be observed macroscopically in tissue culture wells (Atkinson et al., J. Cellular Biochem. 65: 325-339, 1997). BP concentrations equal or greater than 20 ng/ml were required for spheroid formation. No spheroid forms in the absence of BP or at concentrations less than 10 ng/ml (see following table). In this assay, 10T1/2 mesenchymal stem cells act as in vitro models for the precursor cells recruited to a natural defect.
  • [0044]
    We employed the same assay to test the bioactivity of BP released from 1% loaded nanospheres. BP was eluted from nanospheres at 37° C. in a 5% CO2 humidified incubator. After 24 hours 16% BP is released; and between 24 hours and 7 days, 7% BP was released (FIG. 2). The supernatant was collected, serial dilutions were made, and the supernatant was added to 10T1/2 micromass cultures. BP released from nanospheres at both time points formed spheroids at concentrations greater than 20 ng/ml, but not at concentrations between 0 and 10 ng/ml (see following table). Non-encapsulated BP also formed spheroids at concentrations greater than 20 ng/ml, but not at concentrations between 0 and 10 ng/ml. We conclude that both nanosphere encapsulation and release of BP does not inhibit BP bioactivity.
  • [0000]
    Spheroid formation (− = no spheroid
    formation; + = spheroid formation):
    BP concentration (ng/ml)
    state of used BP 0-10 20-1000
    non-encapsulated BP +
    released from nanospheres (24 h) +
    released from nanospheres (168 h) +
  • [0045]
    To determine the effect of BP slow release in the direct presence of micromass cultures, the following assay was performed. Nanospheres were washed for 24 hours and the supernatant was discarded. The nanospheres were then added to micro mass cultures at a quantity such that 10 or 25 ng/ml of BP would be released over 24 hours, Release of 25 ng/ml resulted in spheroid formation whereas release of 10 ng/ml did not form spheroids (FIG. 5). Similarly, the addition of 10 ng of non-encapsulated BP per ml did not form a spheroid whereas the addition of 25 ng of non-encapsulated BP per ml did form a spheroid. Regarding the specific in vitro set-up, we conclude that slow release of BP over 24 hours is as effective as a single dose of BP.
  • [0046]
    To determine whether the BP released from nanospheres was as chondrogenic as non-encapsulated BP, spheroids were analyzed for type II collagen and proteoglycan content. 10T1/2 spheroids from the above assay that had formed with 1 μg of released BP per ml or 1 μg of non-encapsulated BP per ml were tested histologically with Azure and H+E stains and immunocytochemically with antibodies to type II collagen after 7 days. Both encapsulated and non-encapsulated BP induced cartilage markers such as type II collagen, proteoglycan, and round cell shape. In addition, no qualitative differences were observed between encapsulated and non-encapsulated BP with respect to cell quantity, viability, morphology, or organization. We conclude that BP retains full chondrogenic capacity after release from nanospheres.
  • [0047]
    The in vitro models used for determining the chondroinductive effect of BP differ from the in vivo case by the fact that in the in vitro case the precursor cells are present in an appropriate number and in an appropriate distribution whereas in the in vivo case the precursor cells first have to populate the defect and for this reason have to migrate into the defect. Only in the latter case and for achieving repair cartilage which resembles natural cartilage to a high degree, it is essential for the BP to be released over a prolonged time period according to a specific release profile.
  • EXAMPLE
  • [0048]
    The following example shows that BP released from nanospheres induces cartilage repair in chondral defects in vivo whereby virtually all cells recruited to the defect become chondrocytes, whereby the cell structure obtained is ordered, and whereby a hyaline matrix is built up.
  • [0049]
    Using a sheep model, unilateral defects of 0.5 mm width, 0.5 mm depth and 8 to 10 mm length were created in the trochlear groove of the patella. The defects did not penetrate the subchondral bone. The sheep. employed in this study were seven years old and displayed degenerative symptoms, including brittle bones, chondromalacia, and subchondral cysts. Because of their advanced age and degenerative symptoms, these animals probably have decreased numbers of precursor cells. The defects were then dressed according to Hunziker and Rosenberg (J. Bone Joint Surg. 78A(5): 721-733. 1996) with minor changes. Briefly. after enzymatic proteoglycan removal with Chondroitinase AC, 2.5 μl of a solution containing 200 units Thrombin per ml was placed in the defect. Then. a paste was filled into the defect. the paste containing per ml: 60 mg Sheep Fibrinogen (Sigma), 88 mg Gelfoam (Up john) and either 10 μg of BP-nanospheres or 10 μg of BP-nanospheres plus 80 ng rhIGF-1 (R+D Systems).
  • [0050]
    The nanospheres used were the nanospheres as specified in the description regarding FIG. 2 and they were loaded with 1% (w/w) of BP.
  • [0051]
    Assuming that the in vitro determined release rate is approximately the same as for the in vivo case. 10 to 20 ng BP per ml were released during the first 24 hours and approximately 0.1 to 1 ng per day for the following approximately 60 days.
  • [0052]
    After eight weeks, necropsies were performed. The repaired cartilage histology showed that virtually all of the precursor cells were differentiated to chondrocytes throughout the defect. In addition, there was an ordered cartilage appearance with cells on the top being more flattened morphologically than cells in the center and with the presence of ordered. stacked chondrocytes in the lowest zone. The repaired cartilage was fully integrated into the endogenous tissue. In addition. the cartilage repaired with only BP-nanospheres was not significantly different from the cartilage repaired using BP-nanospheres plus IGF-1.
  • [0053]
    In conclusion, these results demonstrate that BP released from nanospheres is sufficient for cartilage repair and that no additional factor is required (such as e.g recombinant factor IGF-1). Using the inventive device constitutes a one step method for cartilage repair, whereby the nanosphere release of BP is sufficient for differentiation of virtually all of the precursor cells to chondrocytes and for induction of an. ordered cartilage structure.
  • OTHER PUBLICATIONS
  • [0000]
    • Archer C W, Morrison E H, Bayliss M T, Ferguson M W: The development of articular cartilage: II. The spatial and temporal patterns of glycosaminoglycans and small leucine rich proteoglycans; J. Anat (ENGLAND) 189 (Pt 1); 23-35 (1996)
    • Atkinson B L, Fantle, K S, Benedict J J, Huffer W E, Gutierrez-Hartmann A: A Combination of Osteoinductive Bone Proteins Differentiates Mesenchymal C3H/10T1/2 Cells Specifically to the Cartilage Lineage; J. Cellular Biochem. 65: 325-339 (1997).
    • Celeste A J, Iannazzi J A, Taylor R C, Hewick R M, Rosen V, Wang E A, Wozney J M: Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone; Proc Nat. Acad Sci USA, December, 87(24): 9843-7 (1990)
    • Denker A E, Nicoll S B, Tuan R S: Formation of cartilage-like spheroids by micromass cultures of murine C3H10T1/2 cells upon treatment with transforming growth factor β1′; Differentiation 59(1): 25-34 (1995)
    • Denker A E, Nicoll S B, Tuan R S: 41st Annual Meeting Orthop, Res. Society. (abstract): 465 (1995)
    • Flechtenmacher J, Huch K, Thenar E J, Mollenhauer J A, Davies S R, Schmid T M, Puhl W, Sampath T K, Aydelotte M B, Kuettner K E: Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes; Arthritis Rheum, November, 39(11): 1896-904 (1996)
    • Hunziker E B and Rosenberg L C: Repair of Partial-Thickness Defects in Articular Cartilage Cell Recruitment from the Synovial Membrane; J. Bone Joint Surgery 78-A(5): 721-733 (1996)
    • Kim S, Turker M S, Chi E Y, Sela S, Martin G M: Preparation of multivesicular liposomes: Bioch, et Biophys. Acta 728:339-348 (1983)
    • Landry F B: Degradation of Poly (D,L-lactic acid) Nanoparticles in artificial gastric and intestinal fluids; in vivo uptake of the nanoparticles and their degradation products; Thesis for the Dept. of Biochemistry, Pharmacy, and Food Chemistry of the Johann Wolfgang Goethe University in Frankfurt, Germany
    • Luyten F P, Cunningham N S, Ma S, Muthukurnaran N, Hammonds R G, Nevins W B, Woods W I, Reddi A H: Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation; J Biol Chem, 264(23): 13377-80 (1989)
    • Massague J: TGFβ Signaling: Receptors, Transducer, and Mad Proteins; Cell 85: 947-950 (1996)
    • Mathiowitz E, Jacob J S, Jong Y S, Carino G P, Chickering D E, Chaturvedi P, Santos C A, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C: Biologically erodable micro spheres as potential oral drug delivery systems; Nature 386: 410-4 (1997)
    • Morrison E H, Ferguson M W, Bayliss M T, Archer C W: The development of articular cartilage: I. The spatial and temporal patterns of collagen types; J Anat (ENGLAND) 189(Pt 1): 9-22 (1996)
    • Mow V C, Ratcliff A, Poole A R: Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures; Biomaterials 13(2): 67-97 (1992)
    • Sailor L Z, Hewick R M, Morris E A: Recombinant human bone morphogenetic Protein-2 maintains the articular chondrocyte phenotype in long-term culture; J. Orthop. Res. 14: 937-945 (1996)
    • Urist M R: Bone: formation by autoinduction; Science 150: 893-899 (1965)
    • Wang E A, Rosen V, D'Alessandro J S, Bauduy M. Cordes P, Harada T, Israel D I, Hewick R M, Kerns K M, LaPan P. Luxenberg D P, McQuaid D, Moutsatsos I, Nove J, Wozney J M: Recombinant human bone morphogenetic protein. induces bone formation; Proc Natl Acad Sci USA, 87(6): 2220-4 (1990)
    • Wowey J M, Rosen V, Celeste A J, Mitsock L M, Whitters M J, Kriz R W, Hewick R M, Wang E A: Novel Regulators of bone formation: molecular clones and activities; Science 242: 1528-34 (1988)

Claims (21)

1-23. (canceled)
24. A composition comprising:
a chondroinductive protein mixture; and
a delivery system having an initial first release rate (% total protein mixture load/time) greater than a subsequent second release rate (% total protein mixture load/time).
25. The composition of claim 24, wherein the first rate is greater than 10% per day.
26. The composition of claim 24, wherein the second rate is less than 1% per day.
27. The composition of claim 24, wherein the delivery system has a third release rate.
28. The composition of claim 27, wherein the third release rate is greater than 0.1% per day.
29. The composition of claim 27, wherein the third release rate occurs temporally before the second release rate.
30. The composition of claim 24, wherein the protein mixture comprises a bone derived protein.
31. The composition of claim 24, wherein the delivery system comprises nanospheres.
32. The composition of claim 24, further comprising a matrix.
33. The composition of claim 32, wherein the matrix comprises a collagen.
34. A composition comprising:
a chondroinductive protein mixture; and
a delivery system having an initial first release rate greater than 10% total protein mixture load per day and a subsequent second release rate less than 1% total protein mixture load per day.
35. The composition of claim 34, wherein the delivery system has a third release rate.
36. The composition of claim 35, wherein the third release rate is greater than 0.1% per day.
37. The composition of claim 35, wherein the third release rate occurs temporally before the second release rate.
38. The composition of claim 34, wherein the protein mixture comprises a bone derived protein.
39. The composition of claim 34, wherein the delivery system comprises nanospheres.
40. The composition of claim 34, further comprising a matrix.
41. The composition of claim 40, wherein the matrix comprises a material selected from the group consisting of type I collagen, type II collagen and hyaluronic acid.
42. The composition of claim 40, wherein the matrix comprises type I collagen.
43. A composition comprising:
a bone derived chondroinductive protein mixture;
a biodegradable matrix including collagen; and
a nanosphere delivery system having an initial first release rate greater than 10% total protein mixture load per day and a subsequent second release rate less than 1% total protein mixture load per day.
US12463108 1997-08-14 2009-05-08 Composition And Device For In Vivo Cartilage Repair Abandoned US20090297605A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP19970810567 EP0896825B1 (en) 1997-08-14 1997-08-14 Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US09485594 US6582471B1 (en) 1997-08-14 1998-08-12 Composition and device for in vivo cartilage repair
PCT/EP1998/005100 WO1999008728A1 (en) 1997-08-14 1998-08-12 Composition and device for in vivo cartilage repair
US10386946 US20030236574A1 (en) 1997-08-14 2003-03-11 Composition and device for in vivo cartilagerepair
US11433968 US20060216325A1 (en) 1997-08-14 2006-05-15 Composition and device for in vivo cartilagerepair
US12463108 US20090297605A1 (en) 1997-08-14 2009-05-08 Composition And Device For In Vivo Cartilage Repair

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12463108 US20090297605A1 (en) 1997-08-14 2009-05-08 Composition And Device For In Vivo Cartilage Repair

Publications (1)

Publication Number Publication Date
US20090297605A1 true true US20090297605A1 (en) 2009-12-03

Family

ID=8230340

Family Applications (6)

Application Number Title Priority Date Filing Date
US09485594 Expired - Fee Related US6582471B1 (en) 1997-08-14 1998-08-12 Composition and device for in vivo cartilage repair
US09250370 Expired - Fee Related US6514514B1 (en) 1997-08-14 1999-02-16 Device and method for regeneration and repair of cartilage lesions
US10386946 Abandoned US20030236574A1 (en) 1997-08-14 2003-03-11 Composition and device for in vivo cartilagerepair
US11046674 Active USRE41286E1 (en) 1997-08-14 2005-01-28 Compositions for regeneration and repair of cartilage lesions
US11433968 Abandoned US20060216325A1 (en) 1997-08-14 2006-05-15 Composition and device for in vivo cartilagerepair
US12463108 Abandoned US20090297605A1 (en) 1997-08-14 2009-05-08 Composition And Device For In Vivo Cartilage Repair

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US09485594 Expired - Fee Related US6582471B1 (en) 1997-08-14 1998-08-12 Composition and device for in vivo cartilage repair
US09250370 Expired - Fee Related US6514514B1 (en) 1997-08-14 1999-02-16 Device and method for regeneration and repair of cartilage lesions
US10386946 Abandoned US20030236574A1 (en) 1997-08-14 2003-03-11 Composition and device for in vivo cartilagerepair
US11046674 Active USRE41286E1 (en) 1997-08-14 2005-01-28 Compositions for regeneration and repair of cartilage lesions
US11433968 Abandoned US20060216325A1 (en) 1997-08-14 2006-05-15 Composition and device for in vivo cartilagerepair

Country Status (6)

Country Link
US (6) US6582471B1 (en)
JP (1) JP2001514935A (en)
CA (1) CA2300415C (en)
DE (2) DE69714035D1 (en)
EP (1) EP0896825B1 (en)
WO (1) WO1999008728A1 (en)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20040081704A1 (en) * 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
JP2002537022A (en) * 1999-02-16 2002-11-05 ズルツァー バイオロジクス インコーポレイテッド Apparatus and method for reproducing and repair cartilage lesions
DE69714035D1 (en) * 1997-08-14 2002-08-22 Sulzer Innotec Ag Composition and apparatus for the repair of cartilage tissue in vivo comprising nanocapsules with osteoinductive and / or chondroinductive factors
US6511958B1 (en) 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
JP4272811B2 (en) * 1997-09-05 2009-06-03 マルホ株式会社 Nanocapsule formulations for intra-articular disease treatment
EP1067959A2 (en) 1998-04-03 2001-01-17 Chiron Corporation Use of igf1 for treating articular cartilage disorders
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
WO2000000180A1 (en) * 1998-06-29 2000-01-06 White Spot Ag Utilization of growth factors for the production of medicaments
WO2002022014A1 (en) 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
DE69941304D1 (en) 1998-09-14 2009-10-01 Univ R State determination of a joint and damage precautionary
US9289153B2 (en) * 1998-09-14 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Joint and cartilage diagnosis, assessment and modeling
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
WO2000054797A3 (en) 1999-03-17 2001-01-04 Novartis Ag Pharmaceutical compositions comprising tgf-beta
US7935147B2 (en) 1999-10-20 2011-05-03 Anulex Technologies, Inc. Method and apparatus for enhanced delivery of treatment device to the intervertebral disc annulus
US7052516B2 (en) * 1999-10-20 2006-05-30 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and deformable spinal disc annulus stent
US8128698B2 (en) 1999-10-20 2012-03-06 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US8632590B2 (en) 1999-10-20 2014-01-21 Anulex Technologies, Inc. Apparatus and methods for the treatment of the intervertebral disc
US7615076B2 (en) * 1999-10-20 2009-11-10 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US20030153976A1 (en) * 1999-10-20 2003-08-14 Cauthen Joseph C. Spinal disc annulus reconstruction method and spinal disc annulus stent
US7004970B2 (en) 1999-10-20 2006-02-28 Anulex Technologies, Inc. Methods and devices for spinal disc annulus reconstruction and repair
US7951201B2 (en) * 1999-10-20 2011-05-31 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US8163022B2 (en) 2008-10-14 2012-04-24 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US20020123807A1 (en) * 1999-10-20 2002-09-05 Cauthen Joseph C. Spinal disc annulus reconstruction method and spinal disc annulus stent
US6592625B2 (en) * 1999-10-20 2003-07-15 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and spinal disc annulus stent
US6805695B2 (en) * 2000-04-04 2004-10-19 Spinalabs, Llc Devices and methods for annular repair of intervertebral discs
US6723335B1 (en) * 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
US6932977B2 (en) * 2000-04-14 2005-08-23 Depuy Spine, Inc. Method of inducing or enhancing chondrogenesis with extracellular matrix containing BMP-4
DE20019809U1 (en) * 2000-05-31 2001-07-12 Fraunhofer Ges Forschung Cartilage replacement and biomatrix for the cultivation of cells
EP1290145B1 (en) 2000-05-31 2005-11-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-dimensional skin model
DK1301196T3 (en) 2000-07-19 2004-03-29 Univ Texas Stimulation of bone growth by peptide derivatives of thrombin
US6878166B2 (en) * 2000-08-28 2005-04-12 Ron Clark Method and implant for securing ligament replacement into the knee
WO2002017955A9 (en) 2000-08-30 2003-02-20 Univ Delaware Delivery system for heparin-binding growth factors
WO2002022013A1 (en) 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US6444222B1 (en) * 2001-05-08 2002-09-03 Verigen Transplantation Services International Ag Reinforced matrices
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
US8234097B2 (en) 2001-05-25 2012-07-31 Conformis, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
CA2447694A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods and compositions for articular resurfacing
US20070233269A1 (en) * 2001-05-25 2007-10-04 Conformis, Inc. Interpositional Joint Implant
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US20110071645A1 (en) * 2009-02-25 2011-03-24 Ray Bojarski Patient-adapted and improved articular implants, designs and related guide tools
US7618451B2 (en) 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8500740B2 (en) 2006-02-06 2013-08-06 Conformis, Inc. Patient-specific joint arthroplasty devices for ligament repair
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US20110071802A1 (en) * 2009-02-25 2011-03-24 Ray Bojarski Patient-adapted and improved articular implants, designs and related guide tools
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US20090222103A1 (en) * 2001-05-25 2009-09-03 Conformis, Inc. Articular Implants Providing Lower Adjacent Cartilage Wear
US8083745B2 (en) 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US8882847B2 (en) * 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
WO2003061690A1 (en) * 2002-01-17 2003-07-31 The Board Of Regents, The University Of Texas System Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
WO2003061653A9 (en) * 2002-01-22 2003-12-24 Charlotte Moira Norfo Allerton 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
EP1490477A4 (en) * 2002-04-02 2006-08-30 Univ Rice William M Redifferentiated cells for repairing cartilage defects
US7622562B2 (en) * 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7241874B2 (en) * 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006501977A (en) 2002-10-07 2006-01-19 コンフォーミス・インコーポレイテッドConforMIS, Inc. Minimally invasive joint implant with a three-dimensional contour conforming to the glenoid surface
JP2006505366A (en) 2002-11-07 2006-02-16 コンフォーミス・インコーポレイテッドConforMIS, Inc. The method of treatment were determined and devising meniscus size and shape
KR20050072500A (en) 2002-12-04 2005-07-11 콘포미스 인코퍼레이티드 Fusion of multiple imaging planes for isotropic imaging in mri and quantitative image analysis using isotropic or near-isotropic imaging
WO2004075940A1 (en) * 2003-02-26 2004-09-10 Zimmer Orthobiologics, Inc. Preparation for repairing cartilage tissue, especially articular cartilage defects
USRE43258E1 (en) 2003-04-29 2012-03-20 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US20050064042A1 (en) * 2003-04-29 2005-03-24 Musculoskeletal Transplant Foundation Cartilage implant plug with fibrin glue and method for implantation
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US20090291112A1 (en) * 2003-05-16 2009-11-26 Truncale Katherine G Allograft osteochondral plug combined with cartilage particle mixture
US7488348B2 (en) * 2003-05-16 2009-02-10 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7896917B2 (en) * 2003-10-15 2011-03-01 Biomet Sports Medicine, Llc Method and apparatus for graft fixation
EP2338442B1 (en) 2003-12-11 2013-01-30 Isto Technologies Inc. Particulate cartilage system
WO2005070333A1 (en) * 2004-01-13 2005-08-04 Orthobiologica, Inc. Drug delivery to a joint
US20050222687A1 (en) * 2004-04-02 2005-10-06 Gordana Vunjak-Novakovic Cartilage implant assembly and method for implantation
US7988716B2 (en) * 2004-04-26 2011-08-02 Howmedica Osteonics Corp. Stent for a vascular meniscal repair and regeneration
US8002778B1 (en) 2004-06-28 2011-08-23 Biomet Sports Medicine, Llc Crosspin and method for inserting the same during soft ligament repair
EP1788986A1 (en) 2004-08-30 2007-05-30 Spineovations, Inc. Method of treating spinal internal disk derangement
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US8435551B2 (en) * 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2006116392A3 (en) 2005-04-27 2007-02-08 Peter X Ma Particle-containing complex porous materials
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
WO2007025290A3 (en) * 2005-08-26 2007-10-18 H Davis Adkisson Iv Implants and methods for repair, replacement and treatment of joint disease
JP5225844B2 (en) * 2005-09-02 2013-07-03 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリーEd. Geistlich Soehne Ag Fuer Chemische Industrie Sheet of collagen membrane material for repairing a meniscal tear
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corp. Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
EP1764117A1 (en) 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
KR100720052B1 (en) 2005-10-07 2007-05-18 (주) 차바이오텍 Microsphere or microbead coated with nanoparticle containing growth factor for regenerating cartilaginous tissue
JP5368102B2 (en) 2005-11-17 2013-12-18 バイオミメティック セラピューティクス, インコーポレイテッド Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
CN101384230A (en) * 2005-11-21 2009-03-11 福特真公司 Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints
JP2007191467A (en) * 2005-12-20 2007-08-02 Pentax Corp New cellular function-regulating factor produced by chondrocyte having hypertrophication
EP2649951A3 (en) 2006-02-06 2013-12-25 ConforMIS, Inc. Patient selectable joint arthroplasty devices and surgical tools
JP5484047B2 (en) 2006-06-30 2014-05-07 バイオミメティック セラピューティクス, エルエルシー pdgf- biological matrix composition for treating rotator cuff injury and methods
WO2008021771A4 (en) * 2006-08-07 2009-01-15 Howmedica Osteonics Corp Insertion system for implanting a medical device and surgical methods
US20080033487A1 (en) * 2006-08-07 2008-02-07 Bioduct, Llc Medical device for repair of tissue and method for implantation and fixation
EP2086598B1 (en) 2006-11-03 2015-05-27 BioMimetic Therapeutics, LLC Compositions and methods for arthrodetic procedures
US20080125863A1 (en) * 2006-11-28 2008-05-29 Mckay William F Implant designs and methods of improving cartilage repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
WO2008086486A1 (en) * 2007-01-10 2008-07-17 The Regents Of The University Of Michigan Porous objects having immobilized encapsulated biomolecules
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US9056151B2 (en) * 2007-02-12 2015-06-16 Warsaw Orthopedic, Inc. Methods for collagen processing and products using processed collagen
WO2008101090A3 (en) 2007-02-14 2008-11-27 Conformis Inc Implant device and method for manufacture
WO2009111069A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US20080220044A1 (en) * 2007-03-06 2008-09-11 Semler Eric J Cancellous construct with support ring for repair of osteochondral defects
US8147546B2 (en) 2007-03-13 2012-04-03 Biomet Sports Medicine, Llc Method and apparatus for graft fixation
CA2684040C (en) 2007-04-12 2016-12-06 Isto Technologies, Inc. Method of forming an implant using a mold that mimics the shape of the tissue defect site and implant formed therefrom
WO2008157412A3 (en) 2007-06-13 2009-04-09 Raymond A Bojarski Surgical cutting guide
US20090004455A1 (en) * 2007-06-27 2009-01-01 Philippe Gravagna Reinforced composite implant
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
US8556949B2 (en) 2007-11-14 2013-10-15 DePuy Synthes Products, LLC Hybrid bone fixation element and methods of using the same
US9308068B2 (en) * 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
CA2708147A1 (en) * 2007-12-05 2009-06-18 Musculoskeletal Transplant Foundation Cancellous bone implant for cartilage repair
EP2259807B1 (en) 2008-02-07 2013-04-24 Biomimetic Therapeutics, Inc. Compositions for distraction osteogenesis
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2009111626A3 (en) 2008-03-05 2010-01-14 Conformis, Inc. Implants for altering wear patterns of articular surfaces
CA2717760C (en) * 2008-03-05 2016-03-29 Conformis, Inc. Edge-matched articular implant
US20100010549A1 (en) * 2008-03-05 2010-01-14 Neville Alleyne device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries
EP2303193A4 (en) 2008-05-12 2012-03-21 Conformis Inc Devices and methods for treatment of facet and other joints
US9242026B2 (en) * 2008-06-27 2016-01-26 Sofradim Production Biosynthetic implant for soft tissue repair
GB0813659D0 (en) 2008-07-25 2008-09-03 Smith & Nephew Fracture putty
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
WO2010019781A1 (en) 2008-08-13 2010-02-18 Smed-Ta/Td, Llc Drug delivery implants
US9616205B2 (en) 2008-08-13 2017-04-11 Smed-Ta/Td, Llc Drug delivery implants
US9700431B2 (en) 2008-08-13 2017-07-11 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
ES2647919T3 (en) 2008-08-13 2017-12-27 Smed-Ta/Td, Llc Drug delivery implants
US9358056B2 (en) 2008-08-13 2016-06-07 Smed-Ta/Td, Llc Orthopaedic implant
WO2010030714A8 (en) 2008-09-09 2011-03-10 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US7805920B2 (en) * 2008-11-13 2010-10-05 The Toro Company Lawn mower having steeply inclined exit tunnel and battery access through rear face of mower cutting deck
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US20110060412A1 (en) * 2009-09-08 2011-03-10 Musculoskeletal Transplant Foundation Inc. Tissue Engineered Meniscus Repair Composition
US20110059178A1 (en) * 2009-09-08 2011-03-10 Musculoskeletal Transplant Foundation Inc. Tissue Engineered Meniscus Repair Composition
CA2782137A1 (en) * 2009-12-11 2011-06-16 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US8994666B2 (en) * 2009-12-23 2015-03-31 Colin J. Karpfinger Tactile touch-sensing interface system
US8652153B2 (en) 2010-01-11 2014-02-18 Anulex Technologies, Inc. Intervertebral disc annulus repair system and bone anchor delivery tool
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
US8574614B2 (en) 2010-02-04 2013-11-05 Hwa-Chang Liu Surgical grafts for repairing chondral defects
JP6144049B2 (en) 2010-02-22 2017-06-07 バイオミメティック セラピューティクス,リミテッド ライアビリティ カンパニー Platelet-derived growth factor compositions and methods for treating tendinopathy
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
EP2663637B1 (en) * 2011-01-10 2017-09-27 Noveome Biotherapeutics, Inc. Accs for use in accelerating the healing of connective tissue injuries
EP2754419A3 (en) 2011-02-15 2014-10-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production Prosthesis comprising a knitted spacer fabric and openwork
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production Prosthesis for umbilical hernia
US9526603B2 (en) 2011-09-30 2016-12-27 Covidien Lp Reversible stiffening of light weight mesh
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production Tricot pins
US9155578B2 (en) 2012-02-28 2015-10-13 DePuy Synthes Products, Inc. Expandable fastener
WO2013152026A1 (en) * 2012-04-02 2013-10-10 Academia Sinica Use of apolipoprotein a-1 for promoting bone formation
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production Prothese including a mesh and a consolidation means
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production reinforcement prosthesis of the abdominal wall and method of manufacture
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production Hemostatic patch and method of preparation
US9737294B2 (en) 2013-01-28 2017-08-22 Cartiva, Inc. Method and system for orthopedic repair
KR20150120986A (en) 2013-02-22 2015-10-28 알로소스 Cartilage mosaic compositions and methods
US9724203B2 (en) 2013-03-15 2017-08-08 Smed-Ta/Td, Llc Porous tissue ingrowth structure
KR20150132152A (en) 2013-03-15 2015-11-25 알로소스 Perforated osteochondral allograft compositions
US9408699B2 (en) 2013-03-15 2016-08-09 Smed-Ta/Td, Llc Removable augment for medical implant
US9681966B2 (en) 2013-03-15 2017-06-20 Smed-Ta/Td, Llc Method of manufacturing a tubular medical implant

Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318774A (en) * 1961-03-15 1967-05-09 Squibb & Sons Inc Treatment of osseous and other tissue
US3458397A (en) * 1966-12-08 1969-07-29 Squibb & Sons Inc Process for producing osteogenic material
US3867728A (en) * 1971-12-30 1975-02-25 Cutter Lab Prosthesis for spinal repair
US4002602A (en) * 1974-03-11 1977-01-11 Gideon Goldstein Ubiquitous immunopoietic polypeptide (UBIP) and methods
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4434094A (en) * 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4596574A (en) * 1984-05-14 1986-06-24 The Regents Of The University Of California Biodegradable porous ceramic delivery system for bone morphogenetic protein
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4663358A (en) * 1985-05-01 1987-05-05 Biomaterials Universe, Inc. Porous and transparent poly(vinyl alcohol) gel and method of manufacturing the same
US4678470A (en) * 1985-05-29 1987-07-07 American Hospital Supply Corporation Bone-grafting material
US4743259A (en) * 1986-10-29 1988-05-10 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4795467A (en) * 1985-03-28 1989-01-03 Collagen Corporation Xenogeneic collagen/mineral preparations in bone repair
US4801299A (en) * 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4810691A (en) * 1984-07-16 1989-03-07 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4834757A (en) * 1987-01-22 1989-05-30 Brantigan John W Prosthetic implant
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4902296A (en) * 1986-10-29 1990-02-20 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US4904260A (en) * 1987-08-20 1990-02-27 Cedar Surgical, Inc. Prosthetic disc containing therapeutic material
US4992226A (en) * 1985-03-28 1991-02-12 Collagen Corporation Method of making molds with xenogeneic collagen/mineral preparations for bone repair
US5001169A (en) * 1984-10-24 1991-03-19 Collagen Corporation Inductive collagen-based bone repair preparations
US5002583A (en) * 1985-08-13 1991-03-26 Sandu Pitaru Collagen implants
US5015255A (en) * 1989-05-10 1991-05-14 Spine-Tech, Inc. Spinal stabilization method
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5116738A (en) * 1986-07-01 1992-05-26 Genetics Institute, Inc. DNA sequences encoding
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5192326A (en) * 1990-12-21 1993-03-09 Pfizer Hospital Products Group, Inc. Hydrogel bead intervertebral disc nucleus
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5219576A (en) * 1988-06-30 1993-06-15 Collagen Corporation Collagen wound healing matrices and process for their production
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US5314477A (en) * 1990-03-07 1994-05-24 J.B.S. Limited Company Prosthesis for intervertebral discs and instruments for implanting it
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5387213A (en) * 1991-02-05 1995-02-07 Safir S.A.R.L. Osseous surgical implant particularly for an intervertebral stabilizer
US5390683A (en) * 1991-02-22 1995-02-21 Pisharodi; Madhavan Spinal implantation methods utilizing a middle expandable implant
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
US5425772A (en) * 1993-09-20 1995-06-20 Brantigan; John W. Prosthetic implant for intervertebral spinal fusion
US5510121A (en) * 1988-11-21 1996-04-23 Rhee; Woonza M. Glycosaminoglycan-synthetic polymer conjugates
US5514180A (en) * 1994-01-14 1996-05-07 Heggeness; Michael H. Prosthetic intervertebral devices
US5591234A (en) * 1993-02-01 1997-01-07 Axel Kirsch Post-surgery orthopedic covering
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5629009A (en) * 1989-02-22 1997-05-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5632747A (en) * 1995-03-15 1997-05-27 Osteotech, Inc. Bone dowel cutter
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5716416A (en) * 1996-09-10 1998-02-10 Lin; Chih-I Artificial intervertebral disk and method for implanting the same
US5718707A (en) * 1997-01-22 1998-02-17 Mikhail; W. E. Michael Method and apparatus for positioning and compacting bone graft
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5741685A (en) * 1995-06-07 1998-04-21 Children's Medical Center Corporation Parenchymal cells packaged in immunoprotective tissue for implantation
US5865846A (en) * 1994-11-14 1999-02-02 Bryan; Vincent Human spinal disc prosthesis
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US5908784A (en) * 1995-11-16 1999-06-01 Case Western Reserve University In vitro chondrogenic induction of human mesenchymal stem cells
US6010698A (en) * 1997-03-27 2000-01-04 Campina Melkunie B. V. Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US6042610A (en) * 1987-07-20 2000-03-28 Regen Biologics, Inc. Meniscal augmentation device
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6080579A (en) * 1997-11-26 2000-06-27 Charlotte-Mecklenburg Hospital Authority Method for producing human intervertebral disc cells
US6177406B1 (en) * 1986-07-01 2001-01-23 Genetics Institute, Inc. BMP-3 products
US6179871B1 (en) * 1995-06-07 2001-01-30 Alan A. Halpern Means for cartilage repair
US6187743B1 (en) * 1999-07-22 2001-02-13 Deroyal Industries, Inc. Composition and method for enhancing wound healing
US6206923B1 (en) * 1999-01-08 2001-03-27 Sdgi Holdings, Inc. Flexible implant using partially demineralized bone
US6211157B1 (en) * 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
US6242247B1 (en) * 1996-06-04 2001-06-05 Sulzer Orthopedics Ltd. Method for making cartilage and implants
US6245107B1 (en) * 1999-05-28 2001-06-12 Bret A. Ferree Methods and apparatus for treating disc herniation
US6251143B1 (en) * 1999-06-04 2001-06-26 Depuy Orthopaedics, Inc. Cartilage repair unit
US6340369B1 (en) * 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
US20020009789A1 (en) * 2000-03-21 2002-01-24 Jcr Pharmaceuticals Co., Ltd. Powder containing physiologically active peptide
US20020013627A1 (en) * 1998-10-05 2002-01-31 Ed. Geistlich Soehne Ag Fur Chemische Industrie Switzerland Method for promoting regeneration of surface cartilage in a damaged joint using multi-layer covering
US6344058B1 (en) * 1999-08-13 2002-02-05 Bret A. Ferree Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates
US6352557B1 (en) * 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US20020040004A1 (en) * 1998-10-16 2002-04-04 Benedict James J. Method of promoting natural bypass
US6372257B1 (en) * 1999-06-29 2002-04-16 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
US6514514B1 (en) * 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
US6558949B2 (en) * 1999-12-14 2003-05-06 Byoung-Hyun Min Media for culturing human cells comprising human serum and method for culturing human cells using the same
US6559119B1 (en) * 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6582960B1 (en) * 1998-09-18 2003-06-24 Massachusetts Institute Of Technology Use of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
US20040033212A1 (en) * 2000-07-29 2004-02-19 Thomson Brian Mark Tissue implant
US6723335B1 (en) * 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US20060008530A1 (en) * 2004-07-12 2006-01-12 Isto Technologies, Inc. Tissue matrix system
US20060024373A1 (en) * 2000-11-14 2006-02-02 N.V.R. Labs Ltd. Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
US20060128016A1 (en) * 2002-08-23 2006-06-15 Yasuo Tokushima Fibrin-containing composition
US20070077236A1 (en) * 2003-06-12 2007-04-05 Interface Biotech A/S Method for cell implantation
US20070087032A1 (en) * 2003-12-23 2007-04-19 Cheong-Ho Chang Composition of cartilage therapeutic agents and its application
US20070128155A1 (en) * 2005-12-07 2007-06-07 Isto Technologies, Inc. Cartilage repair methods
US7235255B2 (en) * 2000-06-22 2007-06-26 Spinal Restoration, Inc. Biological bioadhesive compositions and methods of preparation and use
US20080081369A1 (en) * 2004-10-01 2008-04-03 Isto Technologies, Inc. Method for Chondrocyte Expansion with Phenotype Retention

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (en) * 1973-04-09 1983-07-05 Takeda Chemical Industries Ltd
US4172128A (en) * 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
DE2933174A1 (en) 1978-10-06 1980-04-10 Sulzer Ag Implant for partial replacement of a sliding surface of a human joint
US4294753A (en) 1980-08-04 1981-10-13 The Regents Of The University Of California Bone morphogenetic protein process
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4789732A (en) 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
JPS57144756A (en) 1981-03-04 1982-09-07 Koken Kk Impermeable laminated film
US4619989A (en) * 1981-05-05 1986-10-28 The Regents Of The University Of Cal. Bone morphogenetic protein composition
US5656587A (en) 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US4559299A (en) 1983-02-04 1985-12-17 Brown University Research Foundation Inc. Cytotoxicity assays in cell culturing devices
GB2137209B (en) 1983-03-23 1986-10-15 Univ Ramot Repair of cartilage and of bones
US4627982A (en) 1984-07-16 1986-12-09 Collagen Corporation Partially purified bone-inducing factor
JPS6065734U (en) * 1983-10-11 1985-05-10
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4620327A (en) * 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US4789663A (en) 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
US4888366A (en) 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4627853A (en) 1985-05-29 1986-12-09 American Hospital Supply Corporation Method of producing prostheses for replacement of articular cartilage and prostheses so produced
US4681763A (en) 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
JPH0662679B2 (en) 1985-06-21 1994-08-17 新田ゼラチン株式会社 Organization affinity Korah - Gen and its manufacturing method
US4774227A (en) * 1986-02-14 1988-09-27 Collagen Corporation Collagen compositions for bone repair containing autogeneic marrow
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5141905A (en) 1986-07-01 1992-08-25 Rosen Vicki A Dna sequences encoding bmp-7 proteins
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US4952404A (en) 1987-06-19 1990-08-28 President And Fellows Of Harvard College Promotion of healing of meniscal tissue
US5258043A (en) 1987-07-20 1993-11-02 Regen Corporation Method for making a prosthetic intervertebral disc
DE69031483T2 (en) 1989-08-02 1998-02-05 Univ North Carolina A process for cross-linking collagen thereby generated product
US4863732A (en) 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5053050A (en) 1988-04-29 1991-10-01 Samuel Itay Compositions for repair of cartilage and bone
US4904259A (en) 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US4975526A (en) 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5545229A (en) 1988-08-18 1996-08-13 University Of Medicine And Dentistry Of Nj Functional and biocompatible intervertebral disc spacer containing elastomeric material of varying hardness
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
JPH06103268B2 (en) 1989-02-17 1994-12-14 金作 山下 Jewelry method of imaging using the glow viewing instrument and instrument jewelry diamond like
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152791A (en) 1989-12-07 1992-10-06 Olympus Optical Co., Ltd. Prosthetic artificial bone having ceramic layers of different porosity
DE69111021T2 (en) 1990-10-31 1996-01-04 Gendler El A flexible membrane made from organic bone matrix for repairing and restoring bone.
ES2071195T3 (en) 1990-12-19 1995-06-16 Harle Anton Prothesis bone.
US6413511B1 (en) 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5047055A (en) 1990-12-21 1991-09-10 Pfizer Hospital Products Group, Inc. Hydrogel intervertebral disc nucleus
US5171278A (en) 1991-02-22 1992-12-15 Madhavan Pisharodi Middle expandable intervertebral disk implants
US5972884A (en) 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
EP0516901A1 (en) 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5147374A (en) 1991-12-05 1992-09-15 Alfredo Fernandez Prosthetic mesh patch for hernia repair
JPH0648955A (en) 1992-07-29 1994-02-22 Morinaga Milk Ind Co Ltd Activator for digestive tract cell
US5800537A (en) * 1992-08-07 1998-09-01 Tissue Engineering, Inc. Method and construct for producing graft tissue from an extracellular matrix
US5478739A (en) * 1992-10-23 1995-12-26 Advanced Tissue Sciences, Inc. Three-dimensional stromal cell and tissue culture system
US5656492A (en) 1993-02-12 1997-08-12 Brigham And Women's Hospital, Inc. Cell induction device
DE69434651T2 (en) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge BMP-12, BMP-13 and tendon-inducing compositions containing them
EP0692227A1 (en) 1994-07-11 1996-01-17 SULZER Medizinaltechnik AG Sheet implant
US5681310A (en) 1994-07-20 1997-10-28 Yuan; Hansen A. Vertebral auxiliary fixation device having holding capability
DE69522060D1 (en) 1994-09-08 2001-09-13 Stryker Technologies Corp Spinal disc nucleus of hydrogel
DE19503504A1 (en) 1994-09-16 1996-03-21 Metrimed Orvosi Mueszergyarto Instrument set for osteochondral transplant
US5824093A (en) 1994-10-17 1998-10-20 Raymedica, Inc. Prosthetic spinal disc nucleus
US5562736A (en) 1994-10-17 1996-10-08 Raymedica, Inc. Method for surgical implantation of a prosthetic spinal disc nucleus
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1133462C (en) 1995-06-05 2004-01-07 遗传学研究所有限责任公司 Methods and compositions for healing and repair of connective tissue attachment
DE59509135D1 (en) 1995-10-11 2001-05-03 Sulzer Markets & Technology Ag Method for a photo-oxidative treatment of tissues containing collagen
EP0801676A2 (en) 1995-10-20 1997-10-22 Gerd R. Burmester New artificial tissue, method for the production and the use thereof
ES2211895T5 (en) 1995-11-08 2009-10-29 Zimmer Gmbh intervertebral prothesis.
DE69631490D1 (en) * 1995-11-09 2004-03-11 Univ Massachusetts Boston Restoration of the tissue surface with compositions of hydrogel-cell
US5645597A (en) 1995-12-29 1997-07-08 Krapiva; Pavel I. Disc replacement method and apparatus
US5842477A (en) 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
DE69733292T2 (en) * 1996-03-01 2006-04-27 Isotis N.V. A method for in vitro production of bone
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3638614B2 (en) 1996-07-25 2005-04-13 ジェンザイム・コーポレーション Chondrocyte medium composition and culture methods
US5964807A (en) 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
US5928940A (en) 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
US5827328A (en) 1996-11-22 1998-10-27 Buttermann; Glenn R. Intervertebral prosthetic device
WO1998035653A1 (en) 1997-02-13 1998-08-20 Benedict, James, A. Implantable collagen-containing putty material
CN1068793C (en) 1997-04-17 2001-07-25 中国人民解放军第四军医大学全军创伤骨科研究所 Ostenogenesis stimulin injection and its preparing process
US6123731A (en) * 1998-02-06 2000-09-26 Osteotech, Inc. Osteoimplant and method for its manufacture
US6197061B1 (en) 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
JP2002542297A (en) 1999-04-23 2002-12-10 リサーチ コーポレイション テクノロジーズ,インコーポレイテッド Therapeutic compositions and methods for enhancing angiogenesis
US6315992B1 (en) 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
US6419702B1 (en) 1999-08-13 2002-07-16 Bret A. Ferree Treating degenerative disc disease through transplantation of the nucleus pulposis
US6429013B1 (en) 1999-08-19 2002-08-06 Artecel Science, Inc. Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
CA2638625C (en) 1999-12-03 2012-07-24 University Of Leeds Fixation technology for bone repair
US6626945B2 (en) 2000-03-14 2003-09-30 Chondrosite, Llc Cartilage repair plug
US6492327B2 (en) 2000-12-19 2002-12-10 Sulzer Biologics Inc. Isolation of purified TGF- β1 and TGF -β2 from bone tissue
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
EP1438067A4 (en) 2001-09-24 2006-06-14 Verigen Ag Autologous growth factor cocktail composition, method of production and use
WO2004075940A1 (en) 2003-02-26 2004-09-10 Zimmer Orthobiologics, Inc. Preparation for repairing cartilage tissue, especially articular cartilage defects

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318774A (en) * 1961-03-15 1967-05-09 Squibb & Sons Inc Treatment of osseous and other tissue
US3458397A (en) * 1966-12-08 1969-07-29 Squibb & Sons Inc Process for producing osteogenic material
US3867728A (en) * 1971-12-30 1975-02-25 Cutter Lab Prosthesis for spinal repair
US4002602A (en) * 1974-03-11 1977-01-11 Gideon Goldstein Ubiquitous immunopoietic polypeptide (UBIP) and methods
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
US4434094A (en) * 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
US4801299A (en) * 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4596574A (en) * 1984-05-14 1986-06-24 The Regents Of The University Of California Biodegradable porous ceramic delivery system for bone morphogenetic protein
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4810691A (en) * 1984-07-16 1989-03-07 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US5001169A (en) * 1984-10-24 1991-03-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4795467A (en) * 1985-03-28 1989-01-03 Collagen Corporation Xenogeneic collagen/mineral preparations in bone repair
US4992226A (en) * 1985-03-28 1991-02-12 Collagen Corporation Method of making molds with xenogeneic collagen/mineral preparations for bone repair
US4663358A (en) * 1985-05-01 1987-05-05 Biomaterials Universe, Inc. Porous and transparent poly(vinyl alcohol) gel and method of manufacturing the same
US4678470A (en) * 1985-05-29 1987-07-07 American Hospital Supply Corporation Bone-grafting material
US5002583A (en) * 1985-08-13 1991-03-26 Sandu Pitaru Collagen implants
US6177406B1 (en) * 1986-07-01 2001-01-23 Genetics Institute, Inc. BMP-3 products
US5116738A (en) * 1986-07-01 1992-05-26 Genetics Institute, Inc. DNA sequences encoding
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US4743259A (en) * 1986-10-29 1988-05-10 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US4902296A (en) * 1986-10-29 1990-02-20 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US4834757A (en) * 1987-01-22 1989-05-30 Brantigan John W Prosthetic implant
US6042610A (en) * 1987-07-20 2000-03-28 Regen Biologics, Inc. Meniscal augmentation device
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US4904260A (en) * 1987-08-20 1990-02-27 Cedar Surgical, Inc. Prosthetic disc containing therapeutic material
US5219576A (en) * 1988-06-30 1993-06-15 Collagen Corporation Collagen wound healing matrices and process for their production
US5510121A (en) * 1988-11-21 1996-04-23 Rhee; Woonza M. Glycosaminoglycan-synthetic polymer conjugates
US5629009A (en) * 1989-02-22 1997-05-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5015255A (en) * 1989-05-10 1991-05-14 Spine-Tech, Inc. Spinal stabilization method
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
US5314477A (en) * 1990-03-07 1994-05-24 J.B.S. Limited Company Prosthesis for intervertebral discs and instruments for implanting it
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) * 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
US5192326A (en) * 1990-12-21 1993-03-09 Pfizer Hospital Products Group, Inc. Hydrogel bead intervertebral disc nucleus
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5387213A (en) * 1991-02-05 1995-02-07 Safir S.A.R.L. Osseous surgical implant particularly for an intervertebral stabilizer
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5390683A (en) * 1991-02-22 1995-02-21 Pisharodi; Madhavan Spinal implantation methods utilizing a middle expandable implant
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5591234A (en) * 1993-02-01 1997-01-07 Axel Kirsch Post-surgery orthopedic covering
US5425772A (en) * 1993-09-20 1995-06-20 Brantigan; John W. Prosthetic implant for intervertebral spinal fusion
US5514180A (en) * 1994-01-14 1996-05-07 Heggeness; Michael H. Prosthetic intervertebral devices
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5865846A (en) * 1994-11-14 1999-02-02 Bryan; Vincent Human spinal disc prosthesis
US5632747A (en) * 1995-03-15 1997-05-27 Osteotech, Inc. Bone dowel cutter
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US6179871B1 (en) * 1995-06-07 2001-01-30 Alan A. Halpern Means for cartilage repair
US5741685A (en) * 1995-06-07 1998-04-21 Children's Medical Center Corporation Parenchymal cells packaged in immunoprotective tissue for implantation
US5908784A (en) * 1995-11-16 1999-06-01 Case Western Reserve University In vitro chondrogenic induction of human mesenchymal stem cells
US6242247B1 (en) * 1996-06-04 2001-06-05 Sulzer Orthopedics Ltd. Method for making cartilage and implants
US5716416A (en) * 1996-09-10 1998-02-10 Lin; Chih-I Artificial intervertebral disk and method for implanting the same
US5718707A (en) * 1997-01-22 1998-02-17 Mikhail; W. E. Michael Method and apparatus for positioning and compacting bone graft
US6010698A (en) * 1997-03-27 2000-01-04 Campina Melkunie B. V. Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative
US6514514B1 (en) * 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
US6582471B1 (en) * 1997-08-14 2003-06-24 Sulzer Innotec Ag Composition and device for in vivo cartilage repair
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
US6080579A (en) * 1997-11-26 2000-06-27 Charlotte-Mecklenburg Hospital Authority Method for producing human intervertebral disc cells
US6211157B1 (en) * 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
US6582960B1 (en) * 1998-09-18 2003-06-24 Massachusetts Institute Of Technology Use of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
US20020013627A1 (en) * 1998-10-05 2002-01-31 Ed. Geistlich Soehne Ag Fur Chemische Industrie Switzerland Method for promoting regeneration of surface cartilage in a damaged joint using multi-layer covering
US20020040004A1 (en) * 1998-10-16 2002-04-04 Benedict James J. Method of promoting natural bypass
US6206923B1 (en) * 1999-01-08 2001-03-27 Sdgi Holdings, Inc. Flexible implant using partially demineralized bone
US6245107B1 (en) * 1999-05-28 2001-06-12 Bret A. Ferree Methods and apparatus for treating disc herniation
US6251143B1 (en) * 1999-06-04 2001-06-26 Depuy Orthopaedics, Inc. Cartilage repair unit
US6372257B1 (en) * 1999-06-29 2002-04-16 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6187743B1 (en) * 1999-07-22 2001-02-13 Deroyal Industries, Inc. Composition and method for enhancing wound healing
US6352557B1 (en) * 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6344058B1 (en) * 1999-08-13 2002-02-05 Bret A. Ferree Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates
US6340369B1 (en) * 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
US6558949B2 (en) * 1999-12-14 2003-05-06 Byoung-Hyun Min Media for culturing human cells comprising human serum and method for culturing human cells using the same
US20020009789A1 (en) * 2000-03-21 2002-01-24 Jcr Pharmaceuticals Co., Ltd. Powder containing physiologically active peptide
US6723335B1 (en) * 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
US7235255B2 (en) * 2000-06-22 2007-06-26 Spinal Restoration, Inc. Biological bioadhesive compositions and methods of preparation and use
US20040033212A1 (en) * 2000-07-29 2004-02-19 Thomson Brian Mark Tissue implant
US20060024373A1 (en) * 2000-11-14 2006-02-02 N.V.R. Labs Ltd. Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US20060128016A1 (en) * 2002-08-23 2006-06-15 Yasuo Tokushima Fibrin-containing composition
US20070077236A1 (en) * 2003-06-12 2007-04-05 Interface Biotech A/S Method for cell implantation
US20070087032A1 (en) * 2003-12-23 2007-04-19 Cheong-Ho Chang Composition of cartilage therapeutic agents and its application
US20060008530A1 (en) * 2004-07-12 2006-01-12 Isto Technologies, Inc. Tissue matrix system
US20080081369A1 (en) * 2004-10-01 2008-04-03 Isto Technologies, Inc. Method for Chondrocyte Expansion with Phenotype Retention
US20070128155A1 (en) * 2005-12-07 2007-06-07 Isto Technologies, Inc. Cartilage repair methods

Also Published As

Publication number Publication date Type
USRE41286E1 (en) 2010-04-27 grant
US20030236574A1 (en) 2003-12-25 application
US6514514B1 (en) 2003-02-04 grant
DE69714035D1 (en) 2002-08-22 grant
JP2001514935A (en) 2001-09-18 application
DE69714035T2 (en) 2003-03-06 grant
US6582471B1 (en) 2003-06-24 grant
CA2300415A1 (en) 1999-02-25 application
US20060216325A1 (en) 2006-09-28 application
WO1999008728A1 (en) 1999-02-25 application
CA2300415C (en) 2009-10-27 grant
EP0896825A1 (en) 1999-02-17 application
EP0896825B1 (en) 2002-07-17 grant

Similar Documents

Publication Publication Date Title
Boerckel et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration
Haidar et al. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery
O'driscoll Current concepts review-the healing and regeneration of articular cartilage
Alam et al. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2
Buma et al. Tissue engineering of the meniscus
Schmidt et al. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair
Wang Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants
Buma et al. Cross-linked type I and type II collagenous matrices for the repair of full-thickness articular cartilage defects—a study in rabbits
US7041641B2 (en) Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
Yamamoto et al. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein
van Susante et al. Linkage of chondroitin-sulfate to type I collagen scaffolds stimulates the bioactivity of seeded chondrocytes in vitro
US5368858A (en) Methods and compositions for the treatment and repair of defects or lesions in cartilage
Griffith Emerging design principles in biomaterials and scaffolds for tissue engineering
Barrere et al. Advanced biomaterials for skeletal tissue regeneration: Instructive and smart functions
Brown et al. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release
US5470829A (en) Pharmaceutical preparation
Spalazzi et al. In vivo evaluation of a multiphased scaffold designed for orthopaedic interface tissue engineering and soft tissue‐to‐bone integration
Saito et al. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering
Woo et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix
US20010016646A1 (en) Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US20040062753A1 (en) Composite scaffolds seeded with mammalian cells
Reinholz et al. Animal models for cartilage reconstruction
US6013853A (en) Continuous release polymeric implant carrier
US20050159820A1 (en) Member for regenerating joint cartilage and process for producing the same, method of regenerating joint cartilage and artificial cartilage for transplantation
US7901461B2 (en) Viable tissue repair implants and methods of use